EDITORIAL BOARD

Editor-in-Chief

Professor John Fitzpatrick, MB BCh, FRCSI, MCh, FRCS, FC Urol(SA), FRCSGlas, Professor of Surgery, Mater Misericordiae University Hospital and University College Dublin

Editor

Professor Roger Kirby, MA, MD, FRCS(Urol), FEBU, Director, The Prostate Centre, Wimpole Street, London, and Consultant Urologist and Emeritus Professor, St George’s Hospital, London

Editorial Board

Professor John Betteridge, BSc, MB BS, PhD, MD, FRCP, FAHA, Professor of Endocrinology and Metabolism, University College London, and Honorary Consultant Physician, University College Hospitals, London

Dr Nicholas Boon, MD, FESC, FRCP, Consultant Cardiologist, Royal Infirmary of Edinburgh

Professor Culley Carson, MD, FACS, Rhodes Distinguished Professor, Chief of Urology, University of North Carolina, USA

Professor Michael Kirby, MB BS, LRCP, MRCS, FRCP, Visiting Professor, Faculty of Health and Human Science, University of Hertfordshire, and Visiting Professor, The Prostate Centre, Wimpole Street, London

Professor Peter Littlejohns, MD, FRCP, FRCGP, FFPH, Professor of Public Health, King's College London

Dr Heather Payne, MB BS, FRCP, FRCR, Consultant Clinical Oncologist, University College London Hospitals

Professor Roy Pounder, MD, DSc, FRCP, Emeritus Professor of Medicine, University of London

Dr Jonathan Rees, MB ChB, MRCS, MRCGP, DRCOG, GP, Backwell and Nailsea Medical Centre, Bristol

Professor Alan White, PhD, MSc, BSc(Hons), Cert Ed, RN, Professor of Men’s Health, Leeds Metropolitan University

Dr Michael Wyllie, PhD, Chief Scientific Officer, Plethora Solutions, London

Declaration of interests

John Fitzpatrick has given lectures at meetings sponsored by, or has sat on advisory boards of, Sanofi, Astellas, Orion, Millennium, Johnson & Johnson, Janssen-Cilag, GlaxoSmithKline and Pfizer.

Roger Kirby is Director of the privately run Prostate Centre in London. He is an occasional speaker for pharmaceutical companies including GlaxoSmithKline, Sanofi and American Medical Systems.

John Betteridge has received honoraria for advisory boards, lectures and consultancy from Takeda, MSD, Pfizer, Kowa and Lilly.

Nicholas Boon has received honoraria from Aztra Zeneca, Boehringer Ingelheim and Servier, and holds research grants from the British Heart Foundation.

Culley Carson has received honoraria from GlaxoSmithKline, American Medical Systems, Auxillium, Lilly and Pfizer, and research grants from Astellas, Auxillium and Slate.

Michael Kirby has received financial support from the pharmaceutical industry for research, conference attendance, advice and lecturing, including Pfizer, MSD, Lilly, Boehringer Ingelheim, GlaxoSmithKline, Bayer, Astellas and Takeda.

Peter Littlejohns has no financial interests to declare.

Heather Payne has acted as a medical consultant and attended paid advisory board meetings for Astra Zeneca, Sanofi, Ferring, Janssen, Novartis, Ipsen and GlaxoSmithKline.

Roy Pounder is Editor of Alimentary Pharmacology & Therapeutics. He has no financial interests to declare.

Jonathan Rees has received honoraria from GlaxoSmithKline, Ipsen and Eli Lilly. He has no financial interests in companies or research grants.

Alan White is Chair of the Men’s Health Forum. He has no financial interests to declare.

Michael Wyllie is a Director of Plethora Plc, The Urology Company Ltd, Mens Health Ltd and Global Pharma Consulting Ltd. He is non-executive Chairman of Glycomar Ltd. He has acted as a paid consultant to Pfizer, Lilly, Zeus Capital, Crawford Pharmaceuticals, Evolan Ab, Shionogi Inc, Xion Inc and Excalibur Ltd.

Search the Site

Search